U.S. Health Agency Recommends DEA Downlist Cannabis to Schedule III

The U.S. Department of Health and Human Services has asserted that cannabis should be removed from its Schedule I classification and instead be placed in Schedule III of the Controlled Substances Act. This is a historic change from the standing that cannabis is a drug with no potential medicinal uses and high abuse potential. This recommendation was a result of a scientific review President Joe Biden commissioned last year. Bloomberg first reported the development. The DEA has the ultimate authority here, but the research done may impact their decision. Regardless of what the DEA decides, cannabis will still be considered unlawful according to the federal government if it is designated as a Schedule III drug. The HHS Secretary Xavier Becerra announced in the June that the review to reschedule cannabis from Schedule I would be concluded by the end of the year. If this succeeds, it will have a significant effect on researchers who were critical of the classification that makes it difficult to gain access to studies. Additionally, this will provide the marijuana industry with taxes they are currently unable to attain. As the story is still developing, the Hawaii Psychedelics Task Force had their maiden gathering as they look to potentially legalize psychedelics. In an unprecedented move, a top federal health agency is recommending that cannabis be placed on Schedule III of the Controlled Substances Act. This recommendation, made by the U.S. Food and Drug Administration (FDA), was released by the Drug Enforcement Administration (DEA) in a historic declaration.

The U.S. Food and Drug Administration (FDA) is suggesting that cannabis be reclassified into Schedule III of the Controlled Substances Act, a groundbreaking moment for the drug. The Drug Enforcement Administration (DEA) unveiled the recommendation, which has never been done before.

To read the full article, click the link below: Read More